News. Analysis. Insight.™ - 100 Years of Journalistic Excellence

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of life-threatening diseases. Co. focuses its development on vaccines for use in high-risk populations for infectious disease targets for which there are significant U.S. needs, vaccines for general pediatric or adult populations for infectious disease applications, and cancer vaccines or immunotherapies. All of Co.'s potential products are in research and development phase. Co. generates revenue from research and development agreements with pharmaceutical collaborators and grant and contract arrangements with government entities.

Industry	Health
Sector	Biotechnology
# of Employees	147
Shares Outstanding	51.8M
Market Cap	140.4M
Enterprise Value	98.4M

52-Week High	$5.51
52-Week Low	$1.14
P/E Ratio	-3.82
EPS	-$0.71/shr
Dividend	-
Yield	-

Dr. R. Gordon Douglas M.D.

Chairman

Mr. Vijay B. Samant

Chief Executive Officer; President

Ms. Jill M. Church

Chief Financial Officer; Secretary; Vice President

Dr. David C. Kaslow M.D.

Chief Scientific Officer

Dr. Alain P. Rolland Ph.D.

Senior Vice President

Mr. Kevin R. Bracken

Vice President

Dr. Robin M. Jackman Ph.D.

Vice President

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Stock Updates provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs